Treatment of symptomatic uterine leiomyomas with selective progesterone receptor modulators

Treatment for uterine fibroids: Searching for effective drug therapies

“…Clinical trials involving asoprisnil have reported reversible suppression of menstruation and variable effects on ovulation (Phase I);[29] reduced fibroid size in a dose-dependent manner (5, 10 and 25 mg), and a similar effect on improvement with menorrhagia with a 28–83% amenorrhea rate (Phase II);[29]improved dysfunctional bleeding and reduce fibroid size (Phase III). [19] These results are again promising, however, SPRMs like asoprisnil have not yet received FDA approval due to concerns over the effect of these agents on the endometrium.…”